Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'
Barclays Morning Research Summary: Commodities, Comcast And Healthcare In Focus
Barclays Initiates 2 Cellular Cancer Therapy Plays With Equal-Weight Rating
Jonathan Eckard Recent News
Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside
Why Citigroup Placed An $85 Price Target On Shares Of Alkermes
Citi Analyst Defends Intercept Pharmaceuticals
UPDATE: Citigroup Reiterates on Epizyme Awaiting Further Clarity
UPDATE: Citigroup Upgrades Amarin on Valuation
UPDATE: Citigroup Upgrades Onconova Therapeutics on Favorable Risk-Reward
UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities
UPDATE: Citigroup Downgrades ArQule on Increased Uncertainty Around Lead Cancer Drug Candidate
UPDATE: Citigroup Lowers PT on Vical on Near-Term Challenges
UPDATE: Citigroup Lowers PT on Amarin Following Lighter 2Q13 Sales
Leerink Swann Rates Medivation (MDVN) Market Perform